v3.26.3
Segment Reporting - Schedule of Segment Profit or Loss, Including Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]                
Collaboration revenue $ 0     $ 1,741     $ 3,381 $ 5,277
Type of Revenue [Extensible List] us-gaap:LicenseMember     us-gaap:LicenseMember     us-gaap:LicenseMember us-gaap:LicenseMember
Less:                
Total operating expenses $ 32,247     $ 36,476     $ 99,762 $ 118,260
Loss from operations (32,247)     (34,735)     (96,381) (112,983)
Other income (expense):                
Interest income 1,409     2,575     4,831 8,832
Change in fair value of stock price appreciation milestones 151     (90)     (509) 117
Other income 0     0     0 93
Total other income 1,560     2,485     4,322 9,042
Net loss (30,687) $ (30,159) $ (31,213) (32,250) $ (34,070) $ (37,621) (92,059) (103,941)
Segment Reporting [Member]                
Segment Reporting [Line Items]                
Collaboration revenue 0     1,741     3,381 5,277
Less:                
Personnel costs 9,652     10,997     31,497 33,383
Clinical programs 7,504     6,065     21,102 18,126
Research activities 992     1,100     3,784 5,406
Facilities costs 4,580     6,113     13,222 18,078
Other segment expenses [1] 9,519     12,201     30,157 43,267
Total operating expenses 32,247     36,476     99,762 118,260
Loss from operations (32,247)     (34,735)     (96,381) (112,983)
Other income (expense):                
Interest income 1,409     2,575     4,831 8,832
Change in fair value of stock price appreciation milestones 151     (90)     (509) 117
Other income 0     0     0 93
Total other income 1,560     2,485     4,322 9,042
Net loss $ (30,687)     $ (32,250)     $ (92,059) $ (103,941)
[1] Other segment expenses include stock compensation expense, depreciation, legal fees, general and administrative expenses, and corporate expenses.